Developer docs
API playgroundTry for free, no card

Search company profiles

Sever Pharma Solutions

Full company profile

uuid0007yn5

Namestring
Sever Pharma Solutions
Legal namestring
Sever Pharma Solutions
Company typeenum
Private
Founded yearint
1975
Descriptiontext

Sever Pharma Solutions is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Malmö, Sweden, with a wholly owned US subsidiary in Putnam, Connecticut (Foster Delivery Science, acquired 2021) and a sales office in Baarn, Netherlands. Founded in 1975 as part of Ferrosan, the company has operated under several corporate parents (Pharmacia, Ferring, QPharma) and is currently owned by Nordic Group BV, having rebranded to its current name in 2021. The company employs approximately 380 people globally and operates roughly 38,300 square meters of facility space across its two main manufacturing sites.

The company's core offering is end-to-end pharmaceutical development and manufacturing services built around four integrated pillars: Development Services, Analytical Services, Regulatory Affairs Services, and Manufacturing Services. These are enabled by six technical capabilities: Hot Melt Extrusion (HME) for bioavailability enhancement of BCS Class II/IV molecules, injection molding, controlled-release polymer-based dosage forms, solid dosage forms, aseptic fill and finish, and high-potency handling up to OEB6. The product portfolio is anchored on four categories: high-potent/cytotoxic/hormonal drug product manufacturing (including DEA Schedule 3-5 controlled substances), polymer-based delivery systems (implants, vaginal rings, intrauterine systems, intratumoral and ocular implants down to 100s of microns), hot melt extrusion for bioavailability enhancement, and prefilled syringe and autoinjector assembly. Sever Pharma Solutions is differentiated by a library of over 100 twin-screw extrusion designs, co-extrusion technology for multi-layer reservoir and matrix systems, and multi-jurisdictional GMP certification (FDA, EMA, Swedish MPA).

The business model is B2B enterprise contract services for pharmaceutical and biotech clients requiring specialized polymer-based drug delivery and high-potency containment. Revenue is generated through project-based contracts (development, clinical trial material production, technology transfer) and commercial supply agreements; pricing is quote-based and not publicly disclosed. Sever Pharma Solutions sells directly through an enterprise field sales motion and a global business development function led by Ulrike Foley, supplemented by presence at major industry conferences (CPhI Worldwide, DDF, Nordic Life Science Days, AAPS PharmSci360, Contract Pharma) and technical content marketing (whitepapers, videos, articles). Customer base spans pharmaceutical companies requiring CDMO services for complex delivery systems (hormone therapy, contraception, HIV prevention, oncology implants, pain therapeutics) and specialty biotechs developing novel formulations.

Short descriptiontext

Sever Pharma Solutions is a privately held Swedish CDMO specializing in polymer-based drug delivery systems and high-potency (OEB6) pharmaceutical manufacturing, serving pharma and biotech clients globally from facilities in Sweden and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMalmö, Sweden
HQ citystring
Malmö
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, high potent drug manufacturing, polymer drug delivery systems, hot melt extrusion, aseptic fill finish
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

Full-service CDMO providing end-to-end pharmaceutical development and manufacturing services including formulation development, clinical trial material production, analytical services, regulatory affairs support, and commercial manufacturing. Revenue generated through project-based contracts, technology transfer fees, and commercial supply agreements.

severpharmasolutions.com
2Commercial Product Manufacturing
TypeManaged Services
Description

Manufacturing and supply of pharmaceutical products including polymer-based dosage forms (vaginal rings, implants), solid dosage forms, and aseptically filled syringes. Revenue from commercial batch production and supply agreements.

severpharmasolutions.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sever Pharma Solutions is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, analytical, regulatory, and manufacturing services for high-potency drug products and polymer-based controlled-release dosage forms. Its core offerings cover manufacturing of high potent APIs up to OEB6, polymer-based delivery systems (implants and vaginal rings), hot melt extrusion for bioavailability enhancement, and aseptic fill-and-finish for prefilled syringes and autoinjectors. Services span feasibility screening, formulation development, clinical trial material production, regulatory affairs support, and commercial supply for pharmaceutical and biotech clients globally.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sever Pharma Solutions is a Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for highly potent drugs. The company operates a unified platform with four integrated service pillars: Development Services, Analytical Services, Regulatory Affairs Services, and Manufacturing Services. These services are enabled by six core technical capabilities: Hot Melt Extrusion, Injection Molding, High-Potent Dosage Forms, Controlled Release Polymer-Based Dosage Forms, Solid Dosage Forms, and Aseptic Fill and Finish. The product portfolio centers on four main offerings: High Potent Drug Product Manufacturing (handling APIs up to OEB6), Polymer-Based Delivery Systems (implants and vaginal rings), Hot Melt Extrusion for bioavailability enhancement, and Prefilled Syringes & Autoinjector Assembly. All capabilities are designed to work synergistically, enabling the company to support drug product development from early feasibility through clinical trials to commercial supply.

Product and service8 records
1High Potent Drug Product Manufacturing
CategoryContract Manufacturing Services
Description

Contract manufacturing of pharmaceutical products containing highly potent APIs up to OEB6 (Occupational Exposure Band 6) and DEA Controlled Substances (Schedule 3-5), with advanced containment systems ensuring safe handling. Targeted at pharmaceutical and biotech clients requiring specialized high-potency manufacturing capabilities.

2Polymer-Based Delivery Systems
CategoryContract Manufacturing Services
Description

Contract manufacturing of polymer-based implants and vaginal rings using extrusion, co-extrusion, and injection molding technologies for controlled and extended drug release. Targeted at pharmaceutical companies developing polymer-based sustained-release therapeutics in chronic disease, women's health, HIV prevention, and pain management.

3Hot Melt Extrusion Services
CategoryContract Manufacturing Services
Description

Contract hot melt extrusion services for bioavailability enhancement of poorly water-soluble drugs (BCS Class II molecules), taste masking, and gastro protection of pH-sensitive drugs. Targeted at pharmaceutical clients requiring solubilization and solid dispersion formulation development.

4Prefilled Syringes and Autoinjector Assembly
CategoryContract Manufacturing Services
Description

Contract manufacturing and fully automated assembly with visual inspection for prefilled syringes (0.2ml to 50ml) and autoinjectors, including high-potent and cytotoxic injectable drugs. Targeted at pharmaceutical companies needing sterile injectable drug-device combination product manufacturing.

5Pharmaceutical Development Services
CategoryDevelopment Services
Description

Pharmaceutical development services including feasibility screening, formulation development, clinical trial material production, and technology transfer designed with scale-up in mind. Targeted at pharmaceutical and biotech clients needing early to late-stage development support for complex dosage forms.

6Analytical Services
CategoryAnalytical Services
Description

cGMP analytical services including method development and validation, project support from early to late-stage development, commercial batch release testing, and stability testing for all ICH climatic zones. Targeted at pharmaceutical clients requiring comprehensive analytical and release testing for complex dosage forms.

7Regulatory Affairs Services
CategoryRegulatory Services
Description

Regulatory affairs expertise for polymeric dosage forms and drug-device combinations, supporting the development phase, registration process, and post-approval changes including CTD structure compilation. Targeted at pharmaceutical clients seeking regulatory pathway support for combination products across EU and US.

8Manufacturing Services
CategoryContract Manufacturing Services
Description

Pharmaceutical manufacturing services including facility design, equipment selection, process development, technology transfers, serialization with aggregation via Tracelink interface for DSCSA and EU Falsified Medicines Directive compliance, and logistics. Targeted at pharmaceutical clients requiring end-to-end commercial manufacturing support.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

Expanded partnership with Silo Pharma, Inc. (Nasdaq: SILO) for development of SP-26 ketamine-loaded polymer implant targeting chronic pain and fibromyalgia. Sever Pharma Solutions is scaling up extrusion processes and continuing analytical testing. Previously supported earlier development stages including validation of delivery system through long-term in-vitro release testing and drug product characterization. If clinically successful, SP-26 could qualify for FDA's streamlined 505(b)(2) regulatory pathway.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hovione is a specialty CDMO with deep expertise in HPAPI handling, hot melt extrusion, and aseptic fill-finish for injectables. It is the closest direct comparable to Sever in terms of high-potency and polymer-based drug delivery capabilities for small molecules.

2Recipharm
TypeDirect peer
Description

Recipharm is a Sweden-headquartered CDMO offering solid dose, sterile fill-finish, and high-potency manufacturing for pharma clients across Europe. Geographic and operational overlap make it a closely comparable European specialty CDMO peer.

TypeDirect peer
Description

Aenova is a European CDMO focused on solid dosage forms, including high-potency capabilities and injectables. Sever competes for similar pharmaceutical clients seeking integrated development-to-commercial services in Europe.

TypeDirect peer
Description

PCI is a global CDMO with strong aseptic fill-finish, clinical-to-commercial supply, and serialization capabilities overlapping Sever's prefilled syringe and autoinjector assembly offerings.

TypeDirect peer
Description

Eurofins' CDMO division offers formulation development, clinical manufacturing, and small-batch commercial supply for APIs and intermediates. It overlaps Sever's development services and analytical support offerings.

TypeBroad incumbent
Description

Lonza is a global top-tier CDMO with broad small-molecule and biologics capabilities, including aseptic fill-finish and high-potency containment. It is a broad incumbent rather than a niche specialist compared with Sever.

TypeBroad incumbent
Description

Catalent is one of the largest global CDMOs offering softgel, oral solid dose, biologics, and aseptic fill-finish. It is a broad incumbent competing for the same pharma client outsourcing budgets but across a much wider portfolio.

TypeBroad incumbent
Description

Cambrex is a CDMO specializing in small-molecule API development and manufacturing with cGMP facilities. While it leans toward API rather than finished drug product, it competes for the same pharma CDMO wallet.

9Tapemark
TypeEmerging player
Description

Tapemark is a US-based contract manufacturer focused on transdermal patches and specialty drug delivery. Its polymer-based delivery focus and contract manufacturing model make it an emerging comparable in Sever's adjacent niche.

TypeEmerging player
Description

Lifecore is a CDMO specializing in sterile injectable fill-finish, prefilled syringes, and premium injectable manufacturing. It competes for similar aseptic and high-value injectable CDMO work but with a narrower product range than Sever.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sever Pharma Solutions

Pharmaceutical CDMO Servicesseverpharmasolutions.com

Sever Pharma Solutions is a privately held Swedish CDMO specializing in polymer-based drug delivery systems and high-potency (OEB6) pharmaceutical manufacturing, serving pharma and biotech clients globally from facilities in Sweden and the US.

What Sever Pharma Solutions does

Sever Pharma Solutions is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Malmö, Sweden, with a wholly owned US subsidiary in Putnam, Connecticut (Foster Delivery Science, acquired 2021) and a sales office in Baarn, Netherlands. Founded in 1975 as part of Ferrosan, the company has operated under several corporate parents (Pharmacia, Ferring, QPharma) and is currently owned by Nordic Group BV, having rebranded to its current name in 2021. The company employs approximately 380 people globally and operates roughly 38,300 square meters of facility space across its two main manufacturing sites.

The company's core offering is end-to-end pharmaceutical development and manufacturing services built around four integrated pillars: Development Services, Analytical Services, Regulatory Affairs Services, and Manufacturing Services. These are enabled by six technical capabilities: Hot Melt Extrusion (HME) for bioavailability enhancement of BCS Class II/IV molecules, injection molding, controlled-release polymer-based dosage forms, solid dosage forms, aseptic fill and finish, and high-potency handling up to OEB6. The product portfolio is anchored on four categories: high-potent/cytotoxic/hormonal drug product manufacturing (including DEA Schedule 3-5 controlled substances), polymer-based delivery systems (implants, vaginal rings, intrauterine systems, intratumoral and ocular implants down to 100s of microns), hot melt extrusion for bioavailability enhancement, and prefilled syringe and autoinjector assembly. Sever Pharma Solutions is differentiated by a library of over 100 twin-screw extrusion designs, co-extrusion technology for multi-layer reservoir and matrix systems, and multi-jurisdictional GMP certification (FDA, EMA, Swedish MPA).

The business model is B2B enterprise contract services for pharmaceutical and biotech clients requiring specialized polymer-based drug delivery and high-potency containment. Revenue is generated through project-based contracts (development, clinical trial material production, technology transfer) and commercial supply agreements; pricing is quote-based and not publicly disclosed. Sever Pharma Solutions sells directly through an enterprise field sales motion and a global business development function led by Ulrike Foley, supplemented by presence at major industry conferences (CPhI Worldwide, DDF, Nordic Life Science Days, AAPS PharmSci360, Contract Pharma) and technical content marketing (whitepapers, videos, articles). Customer base spans pharmaceutical companies requiring CDMO services for complex delivery systems (hormone therapy, contraception, HIV prevention, oncology implants, pain therapeutics) and specialty biotechs developing novel formulations.

Sever Pharma Solutions firmographics

Firmographics
Name
Sever Pharma Solutions
Legal name
Sever Pharma Solutions
Website
https://severpharmasolutions.com
Company type
Private
Founded year
1975
Operating status
Operating
Headcount range
101–250 employees
Short description
Sever Pharma Solutions is a privately held Swedish CDMO specializing in polymer-based drug delivery systems and high-potency (OEB6) pharmaceutical manufacturing, serving pharma and biotech clients globally from facilities in Sweden and the US.
Ownership category
akta.pro rank

Sever Pharma Solutions industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical CDMO services
  • High potent drug manufacturing
  • Polymer drug delivery systems
  • Hot melt extrusion
  • Aseptic fill finish

Where Sever Pharma Solutions is headquartered

Location

Headquarters

HQ city
Malmö
HQ country
Sweden
HQ region
Europe

Offices3 records

Markets served

Sever Pharma Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: Full-service CDMO providing end-to-end pharmaceutical development and manufacturing services including formulation development, clinical trial material production, analytical services, regulatory affairs support, and commercial manufacturing. Revenue generated through project-based contracts, technology transfer fees, and commercial supply agreements.
  2. Commercial Product Manufacturing: Manufacturing and supply of pharmaceutical products including polymer-based dosage forms (vaginal rings, implants), solid dosage forms, and aseptically filled syringes. Revenue from commercial batch production and supply agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Sever Pharma Solutions product offering

Product offering

Core offering

Sever Pharma Solutions is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, analytical, regulatory, and manufacturing services for high-potency drug products and polymer-based controlled-release dosage forms. Its core offerings cover manufacturing of high potent APIs up to OEB6, polymer-based delivery systems (implants and vaginal rings), hot melt extrusion for bioavailability enhancement, and aseptic fill-and-finish for prefilled syringes and autoinjectors. Services span feasibility screening, formulation development, clinical trial material production, regulatory affairs support, and commercial supply for pharmaceutical and biotech clients globally.

Product overview

Sever Pharma Solutions is a Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for highly potent drugs. The company operates a unified platform with four integrated service pillars: Development Services, Analytical Services, Regulatory Affairs Services, and Manufacturing Services. These services are enabled by six core technical capabilities: Hot Melt Extrusion, Injection Molding, High-Potent Dosage Forms, Controlled Release Polymer-Based Dosage Forms, Solid Dosage Forms, and Aseptic Fill and Finish. The product portfolio centers on four main offerings: High Potent Drug Product Manufacturing (handling APIs up to OEB6), Polymer-Based Delivery Systems (implants and vaginal rings), Hot Melt Extrusion for bioavailability enhancement, and Prefilled Syringes & Autoinjector Assembly. All capabilities are designed to work synergistically, enabling the company to support drug product development from early feasibility through clinical trials to commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

  • High Potent Drug Product Manufacturing Contract manufacturing of pharmaceutical products containing highly potent APIs up to OEB6 (Occupational Exposure Band 6) and DEA Controlled Substances (Schedule 3-5), with advanced containment systems ensuring safe handling. Targeted at pharmaceutical and biotech clients requiring specialized high-potency manufacturing capabilities.
  • Polymer-Based Delivery Systems Contract manufacturing of polymer-based implants and vaginal rings using extrusion, co-extrusion, and injection molding technologies for controlled and extended drug release. Targeted at pharmaceutical companies developing polymer-based sustained-release therapeutics in chronic disease, women's health, HIV prevention, and pain management.
  • Hot Melt Extrusion Services Contract hot melt extrusion services for bioavailability enhancement of poorly water-soluble drugs (BCS Class II molecules), taste masking, and gastro protection of pH-sensitive drugs. Targeted at pharmaceutical clients requiring solubilization and solid dispersion formulation development.
  • Prefilled Syringes and Autoinjector Assembly Contract manufacturing and fully automated assembly with visual inspection for prefilled syringes (0.2ml to 50ml) and autoinjectors, including high-potent and cytotoxic injectable drugs. Targeted at pharmaceutical companies needing sterile injectable drug-device combination product manufacturing.
  • Pharmaceutical Development Services Pharmaceutical development services including feasibility screening, formulation development, clinical trial material production, and technology transfer designed with scale-up in mind. Targeted at pharmaceutical and biotech clients needing early to late-stage development support for complex dosage forms.
  • Analytical Services cGMP analytical services including method development and validation, project support from early to late-stage development, commercial batch release testing, and stability testing for all ICH climatic zones. Targeted at pharmaceutical clients requiring comprehensive analytical and release testing for complex dosage forms.
  • Regulatory Affairs Services Regulatory affairs expertise for polymeric dosage forms and drug-device combinations, supporting the development phase, registration process, and post-approval changes including CTD structure compilation. Targeted at pharmaceutical clients seeking regulatory pathway support for combination products across EU and US.
  • Manufacturing Services Pharmaceutical manufacturing services including facility design, equipment selection, process development, technology transfers, serialization with aggregation via Tracelink interface for DSCSA and EU Falsified Medicines Directive compliance, and logistics. Targeted at pharmaceutical clients requiring end-to-end commercial manufacturing support.

Companies that use Sever Pharma Solutions

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Sever Pharma Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Sever Pharma Solutions partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Silo PharmacoreStrategic or Co-development Partner · 14 August 2025Expanded partnership with Silo Pharma, Inc. (Nasdaq: SILO) for development of SP-26 ketamine-loaded polymer implant targeting chronic pain and fibromyalgia. Sever Pharma Solutions is scaling up extrusion processes and continuing analytical testing. Previously supported earlier development stages including validation of delivery system through long-term in-vitro release testing and drug product characterization. If clinically successful, SP-26 could qualify for FDA's streamlined 505(b)(2) regulatory pathway.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Sever Pharma Solutions competitors and assessment

Company assessment

Direct peers

  • Hovione: Hovione is a specialty CDMO with deep expertise in HPAPI handling, hot melt extrusion, and aseptic fill-finish for injectables. It is the closest direct comparable to Sever in terms of high-potency and polymer-based drug delivery capabilities for small molecules.
  • Recipharm: Recipharm is a Sweden-headquartered CDMO offering solid dose, sterile fill-finish, and high-potency manufacturing for pharma clients across Europe. Geographic and operational overlap make it a closely comparable European specialty CDMO peer.
  • Aenova Group: Aenova is a European CDMO focused on solid dosage forms, including high-potency capabilities and injectables. Sever competes for similar pharmaceutical clients seeking integrated development-to-commercial services in Europe.
  • PCI Pharma Services: PCI is a global CDMO with strong aseptic fill-finish, clinical-to-commercial supply, and serialization capabilities overlapping Sever's prefilled syringe and autoinjector assembly offerings.
  • Eurofins CDMO: Eurofins' CDMO division offers formulation development, clinical manufacturing, and small-batch commercial supply for APIs and intermediates. It overlaps Sever's development services and analytical support offerings.

Broad incumbents

  • Lonza CDMO: Lonza is a global top-tier CDMO with broad small-molecule and biologics capabilities, including aseptic fill-finish and high-potency containment. It is a broad incumbent rather than a niche specialist compared with Sever.
  • Catalent (Novo Holdings): Catalent is one of the largest global CDMOs offering softgel, oral solid dose, biologics, and aseptic fill-finish. It is a broad incumbent competing for the same pharma client outsourcing budgets but across a much wider portfolio.
  • Cambrex: Cambrex is a CDMO specializing in small-molecule API development and manufacturing with cGMP facilities. While it leans toward API rather than finished drug product, it competes for the same pharma CDMO wallet.

Emerging players

  • Tapemark: Tapemark is a US-based contract manufacturer focused on transdermal patches and specialty drug delivery. Its polymer-based delivery focus and contract manufacturing model make it an emerging comparable in Sever's adjacent niche.
  • Lifecore Biomedical: Lifecore is a CDMO specializing in sterile injectable fill-finish, prefilled syringes, and premium injectable manufacturing. It competes for similar aseptic and high-value injectable CDMO work but with a narrower product range than Sever.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Sever Pharma Solutions social profiles

Digital presence

Sever Pharma Solutions compliance and trust

Trust signal

Compliance5 records

Sever Pharma Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sever Pharma Solutions leadership team

Management profile

Number of profiles

Profiles13 records

Sever Pharma Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Sever Pharma Solutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sever Pharma Solutions M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sever Pharma Solutions

What does Sever Pharma Solutions do?

Sever Pharma Solutions is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, analytical, regulatory, and manufacturing services for high-potency drug products and polymer-based controlled-release dosage forms. Its core offerings cover manufacturing of high potent APIs up to OEB6, polymer-based delivery systems (implants and vaginal rings), hot melt extrusion for bioavailability enhancement, and aseptic fill-and-finish for prefilled syringes and autoinjectors. Services span feasibility screening, formulation development, clinical trial material production, regulatory affairs support, and commercial supply for pharmaceutical and biotech clients globally.

Is Sever Pharma Solutions a public or private company?

Sever Pharma Solutions is a private company. It is classified as corporate owned and is currently operating.

When was Sever Pharma Solutions founded?

Sever Pharma Solutions was founded in 1975. It employs 101 to 250 people.

Where is Sever Pharma Solutions based?

Sever Pharma Solutions is headquartered in Malmö, Sweden, in the Europe region.

How does Sever Pharma Solutions make money?

Two revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are commercial Product Manufacturing.

Who are Sever Pharma Solutions's main competitors?

Direct peers on record are Hovione, Recipharm, Aenova Group, PCI Pharma Services and Eurofins CDMO. Broad incumbents are Lonza CDMO, Catalent (Novo Holdings) and Cambrex. Emerging players are Tapemark and Lifecore Biomedical.

Does Sever Pharma Solutions have an API?

No public API is recorded for Sever Pharma Solutions.

What industry is Sever Pharma Solutions in?

Sever Pharma Solutions's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals